Gilenya made revenues of $2.8 billion in 20021, with half of that total coming from the US market, although it has started to shrink as a result of increased competition in the market for ...

It will not be the most expensive but it will not be the cheapest – a very effective drug at the same list price as Gilenya.” When NICE assessed Gilenya back in 2012, it said the drug costs ...

A US court has ordered generic drug makers to stop selling a copy of Gilenya in US. The annual sales of Gilenya, a drug used to treat multiple sclerosis, was about $3.3 billion in 2018.

Building upon the established success of Novartis’ Gilenya in Canada, these next-generation disease-modifying therapies (DMTs) offer proven efficacy for MS subtypes with high unmet need ...